J. Marc Pipas

3.2k citations

58 papers · 2.4k indexed · 1 hit paper · h-index 22

Oncology top 2%
Cancer Research top 2%
Molecular Biology top 10%
Surgery top 5%
Pharmacology top 2%

Co-authors: Susan Budinger Daniel D. Karp Charles L. Loprinzi Nicholas J. Petrelli John A. Baron Robert S. Sandler Electra D. Paskett Gideon Steinbach
Topics: Pancreatic and Hepatic Oncology Research (25 papers)Cancer Genomics and Diagnostics (11 papers)Colorectal Cancer Treatments and Studies (11 papers)
Cited by: Cancer Research Oncology Pharmacology
Journals: New England Journal of Medicine Journal of Clinical Oncology Blood
Partner nations: United States United Kingdom Spain

In The Last Decade

J. Marc Pipas

52 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal Cancer

2003 862 citations J. Marc Pipas et al. profile →

Peers

Countries citing papers authored by J. Marc Pipas

Since Specialization

Citations

This map shows the geographic impact of J. Marc Pipas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Marc Pipas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Marc Pipas more than expected).

Fields of papers citing papers by J. Marc Pipas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Marc Pipas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Marc Pipas. The network helps show where J. Marc Pipas may publish in the future.

Co-authorship network of co-authors of J. Marc Pipas

This figure shows the co-authorship network connecting the top 25 collaborators of J. Marc Pipas. A scholar is included among the top collaborators of J. Marc Pipas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Marc Pipas. J. Marc Pipas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE) 2020 ·Annals of Oncology ·Madappa N. Kundranda,Antonio Cubillo Gracián,Syed F. Zafar,(unknown),Johanna C. Bendell,Hana Algül,Fernando Rivera,Eugene R. Ahn,David Watkins,Uwe Pelzer,Veena Charu,Alena Zalutskaya,Geoffrey Kuesters,J. Marc Pipas,Sergio Santillana,Vasileios Askoxylakis,Andrew H. Ko	42
2	Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer 2018 ·Clinical Cancer Research ·(unknown),Emily A. Pace,Sharlene Adams,Michael D. Curley,Victoria Rimkunas,Lin Nie,(unknown),Troy Bloom,Sergio Iadevaia,Jason Baum,(unknown),Akos Czibere,Chrystal U. Louis,Daryl C. Drummond,Ulrik B. Nielsen,Birgit Schoeberl,J. Marc Pipas,Robert M. Straubinger,Vasileios Askoxylakis,Alexey A. Lugovskoy	44
3	CARRIE: A randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer 2018 ·Annals of Oncology ·Andrew H. Ko,Antonio Cubillo,Madappa N. Kundranda,Syed F. Zafar,Eyal Meiri,J. C. Bendell,(unknown),F. Rivera Herrero,(unknown),(unknown),Uwe Pelzer,(unknown),(unknown),(unknown),Geoffrey Kuesters,J. Marc Pipas,Sergio Santillana,Vasileios Askoxylakis	8
4	FG-3019, A Human Monoclonal Antibody to Connective Tissue Growth Factor, Combined with Chemotherapy in Patients with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma 2016 ·Vincent J. Picozzi,J. Marc Pipas,Albert C. Koong,Amato J. Giaccia,Nathan Bahary,Smitha Krishnamurthi,Charles D. Lopez,Peter J. O’Dwyer,Katharina Modelska,(unknown),James Chou,Ming Zhong,Stefan Hemmerich,Dongxia Li,Ewa Carrier,Seth Porter,Thomas B. Neff,Frank H. Valone	8
5	Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed 2015 ·Journal of Clinical Oncology ·Herbert I. Hurwitz,Nikhil Uppal,Stephanie A. Wagner,Johanna C. Bendell,J. Thaddeus Beck,(unknown),John Nemunaitis,Philip J. Stella,J. Marc Pipas,Zev A. Wainberg,Robert Manges,William M. Garrett,Deborah Hunter,Jason Clark,Lance Leopold,Victor Sandor,Richard S. Levy	237
6	Molecular Testing for Lymph Node Metastases as a Determinant of Colon Cancer Recurrence: Results from a Retrospective Multicenter Study 2014 ·Clinical Cancer Research ·Daniel J. Sargent,Qian Shi,Sharlene Gill,Christophe Louvet,Richard B. Everson,Udo Kellner,Thomas E. Clancy,J. Marc Pipas,Murray B. Resnick,Michael O. Meyers,Tsung‐Teh Wu,David G. Huntsman,Pierre Validire,Umar Farooq,Emily S. Pavey,(unknown),(unknown),Yves Fradet	8
7	Results from a Phase 2 Study of Ruxolitinib or Placebo with Capecitabine as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer: The Recap Trial 2014 ·Annals of Oncology ·H. Hurwitz,Nikhil Uppal,(unknown),J. C. Bendell,(unknown),(unknown),John Nemunaitis,Philip J. Stella,J. Marc Pipas,Zev A. Wainberg,Robert Manges,William M. Garrett,Deborah Hunter,Jason Clark,L. Leopold,Richard Levy,V. Sandor	2
8	The Effect of Neoadjuvant Chemoradiation on Pancreatic Cancer-Associated Diabetes Mellitus 2014 ·Pancreas ·Timothy B. Gardner,(unknown),Kerrington D. Smith,Gregory H. Ripple,Richard J. Barth,David A. Klibansky,Thomas A. Colacchio,Bassem I. Zaki,Michael J. Tsapakos,Arief A. Suriawinata,Juan Putra,Gregory J. Tsongalis,Kabir Mody,Stuart R. Gordon,J. Marc Pipas	7
9	Successful retreatment with chemoradiotherapy for local recurrence of pancreatic adenocarcinoma after neoadjuvant therapy and pancreaticoduodenectomy. 2013 ·Europe PMC (PubMed Central) ·(unknown),Bassem I. Zaki,Michael J. Tsapakos,Stuart R. Gordon,Arief A. Suriawinata,Gregory J. Tsongalis,John E. Sutton,J. Marc Pipas	0
10	MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm 2013 ·Cancer Genetics ·(unknown),Ahmad Abou Tayoun,Kristine M. Abo,J. Marc Pipas,Stuart R. Gordon,Timothy B. Gardner,Richard J. Barth,Arief A. Suriawinata,Gregory J. Tsongalis	61
11	Merkel cell polyomavirus and extrapulmonary small cell carcinoma 2013 ·Oncology Letters ·(unknown),Joel A. Lefferts,Jeoffry B. Brennick,Marc S. Ernstoff,Gregory J. Tsongalis,J. Marc Pipas	11
12	Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma 2012 ·Annals of Oncology ·J. Marc Pipas,Bassem I. Zaki,(unknown),Michael J. Tsapakos,Gregory H. Ripple,Arief A. Suriawinata,Gregory J. Tsongalis,Thomas A. Colacchio,Stuart R. Gordon,J. E. G. Sutton,Amitabh Srivastava,Kerrington D. Smith,Timothy B. Gardner,Murray Korc,Thomas Davis,Meir Preis,(unknown),Todd A. MacKenzie,Richard J. Barth	36
13	MicroRNA-10b Expression Correlates with Response to Neoadjuvant Therapy and Survival in Pancreatic Ductal Adenocarcinoma 2011 ·Clinical Cancer Research ·Meir Preis,Timothy B. Gardner,Stuart R. Gordon,J. Marc Pipas,Todd A. MacKenzie,Erin E. Klein,Daniel S. Longnecker,Edward J. Gutmann,Lorenzo F. Sempere,Murray Korc	125
14	Screening for pancreatic cancer in a high-risk population with serum CA 19-9 and targeted EUS: a feasibility study 2011 ·Gastrointestinal Endoscopy ·Richard Zubarik,Stuart R. Gordon,Steven D. Lidofsky,(unknown),J. Marc Pipas,Gary J. Badger,Eric K. Ganguly,James Vecchio	58
15	A Dose Escalation Trial of Biweekly Docetaxel and Gemcitabine with Filgrastim or Pegfilgrastim for the Treatment of Patients with Advanced Solid Tumors 2010 ·Chemotherapy ·Konstantin H. Dragnev,(unknown),J. Marc Pipas,Thomas Davis,James R. Rigas	6
16	Endovascular Recanalization of Symptomatic Portomesenteric Venous Obstruction after Pancreaticoduodenectomy and Radiation 2009 ·Journal of Vascular and Interventional Radiology ·Eric K. Hoffer,(unknown),John M. Gemery,Bassem I. Zaki,J. Marc Pipas	9
17	Atypical teratoid/rhabdoid tumor of the spine in an adult: case report and review of the literature 2007 ·Journal of Neuro-Oncology ·(unknown),(unknown),Eugen B. Hug,Perry A. Ball,Laurence D. Cromwell,J. Marc Pipas,Camilo E. Fadul,Louise P. Meyer,Jonathan P. Park,Jaclyn A. Biegel,Arie Perry,C. Harker Rhodes	45
18	Treatment of progressive metastatic glomus jugulare tumor (paraganglioma)with gemcitabine 2000 ·Neuro-Oncology ·J. Marc Pipas,(unknown)	4
19	Nonconvulsive Status Epilepticus After Intravenous Contrast Medium Administration 1996 ·Epilepsia ·Timothy G. Lukovits,Camilo E. Fadul,J. Marc Pipas,Pétér D. Williamson	4
20	Treatment of patients with pineoblastoma with high dose cyclophosphamide 1996 ·Medical and Pediatric Oncology ·David M. Ashley,(unknown),R D Tien,Herbert E. Fuchs,Michael L. Graham,Joanne Kurtzberg,Janet R. Casey,Janice F. Olson,(unknown),(unknown),Tracy Kerby,(unknown),Elizabeth Stewart,O. Michael Colvin,J. Marc Pipas,Geoffrey McCowage,Roger E. McLendon,Darell D. Bigner,Henry S. Friedman	15

About J. Marc Pipas

J. Marc Pipas is a scholar working on Oncology, Cancer Research and Hepatology, having authored 58 papers that have together received 2.4k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (25 papers), Cancer Genomics and Diagnostics (11 papers) and Colorectal Cancer Treatments and Studies (11 papers). The work is most often cited by research in Cancer Research (796 citations), Oncology (1.3k citations) and Pharmacology (482 citations). J. Marc Pipas has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Susan Budinger, Daniel D. Karp, Charles L. Loprinzi, Nicholas J. Petrelli, John A. Baron, Robert S. Sandler, Electra D. Paskett, Gideon Steinbach, Richard L. Schilsky and Susan Halabi. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact